OPKO HEALTH, INC.
For the period ended Mar 31, 2025. Filed May 1, 2025.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Mar 31, 2025 · Filed May 1, 2025
OPK$1.710.0%Stored close · as of Nov 10, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Condensed Consolidated Balance Sheets as of
CONDENSED CONSOLIDATED BALANCE SHEET
(In thousands, except share and per share data)
| March 31, 2025 | December 31, 2024 | |
|---|---|---|
| ASSETS | ||
| Current assets: | ||
| Cash, cash equivalents and current restricted cash | $435,999 | $431,936 |
| Accounts receivable, net | 96,150 | 118,017 |
| Inventory, net | 64,001 | 56,797 |
| Other current assets and prepaid expenses | 54,441 | 55,339 |
| Assets held for sale | 87,013 | — |
| Total current assets | 737,604 | 662,089 |
| Property, plant and equipment, net | 71,195 | 70,134 |
| Intangible assets, net | 568,518 | 616,613 |
| In-process research and development | 195,000 | 195,000 |
| Goodwill | 476,672 | 529,252 |
| Investments | 12,750 | 54,584 |
| Operating lease right-of-use assets | 47,819 | 54,003 |
| Other assets | 18,769 | 18,537 |
| Total assets | $2,128,327 | $2,200,212 |
| LIABILITIES AND EQUITY | ||
| Current liabilities: | ||
| Accounts payable | $59,370 | $47,071 |
| Accrued expenses | 113,209 | 118,357 |
| Current maturities of operating leases | 9,888 | 12,649 |
| Current portion of convertible notes | 101,242 | 170 |
| Current portion of lines of credit and notes payable | 12,145 | 14,849 |
| Total current liabilities | 295,854 | 193,096 |
| Operating lease liabilities | 38,344 | 48,849 |
| Long term portion of convertible notes | 77,226 | 173,606 |
| Senior secured notes | 245,794 | 245,576 |
| Deferred tax liabilities | 129,435 | 140,799 |
| Other long-term liabilities | 30,011 | 32,838 |
| Total long-term liabilities | 520,810 | 641,668 |
| Total liabilities | 816,664 | 834,764 |
| Equity: | ||
| Common Stock - $0.01 par value, 1,250,000,000 shares authorized; 701,406,697 and 701,350,447 shares issued at March 31, 2025 and December 31, 2024, respectively | 7,015 | 7,015 |
| Treasury Stock - 29,799,907, and 29,799,907 shares at March 31, 2025 and December 31, 2024, respectively | (1,791) | (1,791) |
| Additional paid-in capital | 3,484,068 | 3,481,364 |
| Accumulated other comprehensive loss | (45,006) | (56,130) |
| Accumulated deficit | (2,132,623) | (2,065,010) |
| Total shareholders’ equity | 1,311,663 | 1,365,448 |
| Total liabilities and equity | $2,128,327 | $2,200,212 |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.